Recursion Pharmaceuticals Inc. stock reached a 52-week low, closing at $2.98. The biotechnology company, with a market capitalization of $1.58 billion, now trades 58% below its 52-week high of $7.18.

Its publisher, Hachette, will not release the novel in the United States and will discontinue its U.K. edition, citing its commitment to “original creative expression and storytelling.” By Alexandra ...

Katherine Haan, MBA, is a Senior Staff Writer for Forbes Advisor and a former financial advisor turned international bestselling author and business coach. For more than a decade, she’s helped small ...

Katelyn Peters has a writer and editor for more than five years who focuses on both investing and personal finance content. In addition to her experience in finance, she is also a volunteer editorial ...